Atezolizumab
- Generic Name
- Atezolizumab
- Brand Names
- Tecentriq
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 1380723-44-3
- Unique Ingredient Identifier
- 52CMI0WC3Y
- Background
Atezolizumab is a humanized monoclonal antibody used to prevent the interaction of PD-L1 and PD-1, removing inhibition of immune responses seen in some cancers. This medication is reserved for patients whose tumors express PD-L1, cannot receive platinum-based chemotherapy, or whose tumors do not respond to platinum-based chemotherapy. Atezolizumab was grante...
- Indication
Atezolizumab has approved indications for the following conditions:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Hepatocellular Carcinoma (HCC)
Melanoma
Alveolar Soft Part Sarcoma (ASPS)
- Associated Conditions
- Metastatic Alveolar Soft Part Sarcoma, Metastatic Hepatocellular Carcinoma, Metastatic Melanoma, Metastatic Non-Small Cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Non-Small Cell Lung Carcinoma, Nonsmall Cell Lung Cancer, Stage II, Small Cell Lung Cancer (SCLC), Stage IIIA Non Small Cell Lung Cancer, Triple-Negative Breast Cancer, Unresectable Alveolar Soft Part Sarcoma, Unresectable Hepatocellular Carcinoma (HCC), Unresectable Melanoma
- Associated Therapies
- -
KPMNG Study of MOlecular Profiling Guided Therapy Based on Genomic Alterations in Advanced Solid Tumors II
- First Posted Date
- 2022-09-02
- Last Posted Date
- 2024-11-12
- Lead Sponsor
- Seoul National University Bundang Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT05525858
- Locations
- 🇰🇷
Soonchunhyang University Hospital Bucheon, Bucheon, Korea, Republic of
🇰🇷Chungbuk National University Hospital, Chungju, Korea, Republic of
🇰🇷Keimyung University Dongsan Hospital, Daegu, Korea, Republic of
Atezolizumab for Idiopathic Pulmonary Fibrosis
- First Posted Date
- 2022-08-25
- Last Posted Date
- 2024-08-22
- Lead Sponsor
- Cedars-Sinai Medical Center
- Target Recruit Count
- 24
- Registration Number
- NCT05515627
- Locations
- 🇺🇸
Cedars-Sinai Medical Center, Los Angeles, California, United States
Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification
- Conditions
- Interventions
- First Posted Date
- 2022-08-22
- Last Posted Date
- 2023-08-15
- Lead Sponsor
- M.D. Anderson Cancer Center
- Registration Number
- NCT05510427
Split Course Adaptive Radiation Therapy With Pembrolizumab With/Without Chemotherapy for Treating Stage IV Lung Cancer
- Conditions
- Interventions
- Procedure: Biospecimen CollectionDrug: CarboplatinProcedure: Computed TomographyOther: Fludeoxyglucose F-18Biological: PembrolizumabDrug: Nab-paclitaxelDrug: PemetrexedProcedure: Positron Emission TomographyBiological: AtezolizumabRadiation: Radiation TherapyOther: [18-F] (fluoropropyl)-L-glutamate (FSPG) PET scanBiological: CemiplimabBiological: IpilimumabBiological: Nivolumab
- First Posted Date
- 2022-08-15
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Vanderbilt-Ingram Cancer Center
- Target Recruit Count
- 25
- Registration Number
- NCT05501665
- Locations
- 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States
Investigate the Contribution of Ipatasertib to Neoadjuvant Chemotherapy Plus Atezolizumab in TNBC
- Conditions
- Interventions
- First Posted Date
- 2022-08-12
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Queen Mary University of London
- Target Recruit Count
- 146
- Registration Number
- NCT05498896
- Locations
- 🇬🇧
Barts Health NHS Trust, London, United Kingdom
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT05487235
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇵🇱Uniwersytecki Szpital Kliniczny w Poznaniu, Pozna?, Poland
🇪🇸NEXT Oncology-Hospital Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
Evaluating Novel Therapies in ctDNA Positive GI Cancers
- First Posted Date
- 2022-08-01
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- Georgetown University
- Target Recruit Count
- 20
- Registration Number
- NCT05482516
- Locations
- 🇺🇸
Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia, United States
A Single-arm Trial of Atezolizumab/Platinum/Etoposide for the Treatment of Advanced Large-cell Neuroendocrine Cancer of the Lung
- Conditions
- Interventions
- First Posted Date
- 2022-07-22
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Technische Universität Dresden
- Target Recruit Count
- 67
- Registration Number
- NCT05470595
- Locations
- 🇩🇪
Robert-Bosch-Krankenhaus GmbH, Stuttgart, Germany
🇩🇪Krankenhaus St. Elisabeth und St. Barbara Halle (Saale) GmbH, Halle (Saale), Germany
🇩🇪Charité - Universitätsklinikum Berlin Centrum 12, Medizinische Klinik, Berlin, Germany
Safety and Efficacy of Cyclophosphamide, Sorafenib, Bevacizumab, and Atezolizumab in Pediatric Solid Tumor Patients
- First Posted Date
- 2022-07-21
- Last Posted Date
- 2023-12-22
- Lead Sponsor
- St. Jude Children's Research Hospital
- Target Recruit Count
- 64
- Registration Number
- NCT05468359
- Locations
- 🇺🇸
St. Jude Children's Research Hospital, Memphis, Tennessee, United States
A Study Evaluating Efficacy and Safety of Multiple Treatment Combinations in Patients With Locally Advanced Squamous Cell Carcinoma of the Head and Neck (Morpheus-Head and Neck Cancer)
- Conditions
- Interventions
- First Posted Date
- 2022-07-14
- Last Posted Date
- 2024-08-27
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 12
- Registration Number
- NCT05459129
- Locations
- 🇺🇸
Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
🇦🇺Sir Charles Gairdner Hospital; Medical Oncology, Perth, Western Australia, Australia
🇫🇷Institut de Cancérologie de Lorraine, Vandoeuvre-Les-Nancy, France
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.